The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index; 8 of the 18 sources its claims cite were checked for support.
Teclistamab in Relapsed or Refractory Multiple Myeloma
Open accessAbstract
BACKGROUND: Teclistamab is a T-cell-redirecting bispecific antibody that targets both CD3 expressed on the surface of T cells and B-cell maturation antigen expressed on the surface of myeloma cells. In the phase 1 dose-defining portion of the study, teclistamab showed promising efficacy in patients with relapsed or refractory multiple myeloma. METHODS: In this phase 1-2 study, we enrolled patients who had relapsed or refractory myeloma after at least three therapy lines, including triple-class exposure to an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody. Patients received a weekly subcutaneous injection of teclistamab (at a dose of 1.5 mg per kilogram of body weight) after receiving step-up doses of 0.06 mg and 0.3 mg per kilogram. The primary end point was the overall response (partial response or better). RESULTS: Among 165 patients who received teclistamab, 77.6% had triple-class refractory disease (median, five previous therapy lines). With a median follow-up of 14.1 months, the overall response rate was 63.0%, with 65 patients (39.4%) having a complete response or better. A total of 44 patients (26.7%) were found to have no minimal residual disease (MRD); the MRD-negativity rate among the patients with a complete response or better was 46%. The median duration of response was 18.4 months (95% confidence interval [CI], 14.9 to not estimable). The median duration of progression-free survival was 11.3 months (95% CI, 8.8 to 17.1). Common adverse events included cytokine release syndrome (in 72.1% of the patients; grade 3, 0.6%; no grade 4), neutropenia (in 70.9%; grade 3 or 4, 64.2%), anemia (in 52.1%; grade 3 or 4, 37.0%), and thrombocytopenia (in 40.0%; grade 3 or 4, 21.2%). Infections were frequent (in 76.4%; grade 3 or 4, 44.8%). Neurotoxic events occurred in 24 patients (14.5%), including immune effector cell-associated neurotoxicity syndrome in 5 patients (3.0%; all grade 1 or 2). CONCLUSIONS: Teclistamab resulted in a high rate of deep and durable response in patients with triple-class-exposed relapsed or refractory multiple myeloma. Cytopenias and infections were common; toxic effects that were consistent with T-cell redirection were mostly grade 1 or 2. (Funded by Janssen Research and Development; MajesTEC-1 ClinicalTrials.gov numbers, NCT03145181 and NCT04557098.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
8 of 18 cited sources checked · 5 supported · 0 flagged · accuracy not yet measured
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“In contrast, higher-grade cytokine release syndrome and neurotoxic events have been described after CAR-T administration in patients with multiple myeloma.6,8”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
What the sources say
- Supportedcites [6] source
Table 2 reports grade 3 or higher cytokine release syndrome in 7 of 128 patients and grade 3 neurotoxic effects in 4 of 128 after ide-cel infusion. The Methods identify the treated population as patients with relapsed and refractory multiple myeloma. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites [8] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among 165 patients who received teclistamab, 77.6% had triple-class refractory disease (median, five previous therapy lines).”
- Also stated in: § PATIENTS · plain
“Before study entry, 148 patients (89.7%) had resistance to the previous line of therapy, 128 (77.6%) had triple-class refractory disease, and 50 (30.3%) had penta-drug refractory disease.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > Abstract > RESULTS
Strength:plain· not yet calibratedn = 165Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Also stated in: § PATIENTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Responses occurred in 104 of 165 patients (63.0%; 95% confidence interval [CI], 55.2 to 70.4).”
- Also stated in: § RESULTS · plain
“the overall response rate was 63.0%”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The median duration of progression-free survival was 11.3 months (95% CI, 8.8 to 17.1)”
- Also stated in: § RESULTS · plain
“The median duration of progression-free survival was 11.3 months (95% CI, 8.8 to 17.1).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > Abstract > RESULTS
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The Kaplan–Meier estimate of maintenance of response for at least 12 months was 68.5% (95% CI, 57.7 to 77.1).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Otherwise, response rates were consistent across most clinically relevant subgroups, including patients with high-risk cytogenetic abnormalities and those with penta-drug refractory disease (Fig. S2).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Hypogammaglobulinemia occurred in 123 patients (74.5%) as determined by means of adverse-event reporting, laboratory analyses (IgG level, <500 mg per deciliter), or both”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Strength:plain· not yet calibratedn = 123Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among the 65 patients who had a complete response or better, 30 (46%) had no minimal residual disease (Table S4).”
- Also stated in: § RESULTS · plain
“the MRD-negativity rate among the patients with a complete response or better was 46%”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
Strength:plain· not yet calibratedn = 65Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Negativity for minimal residual disease (at a threshold of 10−5) was reported in 44 patients (26.7%; 95% CI, 20.1 to 34.1).”
- Also stated in: § RESULTS · plain
“A total of 44 patients (26.7%) were found to have no minimal residual disease (MRD)”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“a complete response or better occurred in 65 (39.4%)”
- Also stated in: § RESULTS · plain
“65 patients (39.4%) having a complete response or better”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § RESULTS · plain
- It may state two separate claims as one. 31
- Probably not a substantial claim. 12
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“CAR-T therapy requires that patients have access to specialized care centers and can wait the minimum 4-week period for production, which can result in attrition rates of approximately 10 to 15%,6-8”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
What the sources say
- Partly supportedcites [6] sourceExperimental — accuracy not yet measured
The Patients section (page not available) reports that 12 of 140 enrolled patients discontinued before ide-cel infusion, an attrition rate of about 8.6%, and that some patients received bridging therapy during manufacturing. It does not establish a minimum four-week production period, a requirement for access to specialized care centers, or that waiting caused the discontinuations. (LLM, conf=0.85)
- Partly supportedcites [7] sourceExperimental — accuracy not yet measured
The Discussion and future perspectives section (page unavailable) says CAR T-cell treatment involves a specialized center and that manufacturing takes several days to weeks, during which disease may progress. It does not establish a minimum four-week production period or an attrition rate of approximately 10–15%. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [8] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Such absence of minimal residual disease has been associated with improved overall survival and progression-free survival in patients with myeloma.14-16”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites [14] source
- Supportedcites [15] source
The Introduction states that MRD-negative status is associated with improved progression-free survival (PFS) and overall survival (OS). The Discussion likewise reports prior multiple-myeloma findings for both outcomes; the paper's own OS data were immature, but the claim does not attribute an OS result to this study's analysis. (LLM, conf=0.94)
- Supportedcites [16] source
The Discussion states that MRD negativity is associated with improved survival in both newly diagnosed and relapsed/refractory myeloma. The Introduction links MRD negativity with prolonged progression-free and overall survival, supporting both endpoints in the claim. (LLM, conf=0.90)
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.03), except for cytokine release syndrome (Table S2) and immune effector cell–associated neurotoxicity syndrome, which were graded according to the criteria of the American Society for Transplantation and Cellular Therapy.12”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > END POINTS AND ASSESSMENTS
What the sources say
- Supportedcites [12] source
The citation supports the exception for CRS and ICANS: the paper sets out consensus grading criteria for both in its ‘Consensus on CRS Grading (Table 2)’ and ‘Consensus on ICANS Grading for Adults’ sections (page not available). The citing study’s choice to grade its other adverse events using CTCAE v4.03 is not attributed to this source. (LLM, conf=0.93)
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The primary end point of the phase 2 study was the overall response rate, which was defined as a partial response or better according to the criteria of the International Myeloma Working Group, as assessed by an independent review committee”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > END POINTS AND ASSESSMENTS
What the sources say
- Partly supportedcites [10] sourceExperimental — accuracy not yet measured
The Response criteria section recommends IMWG criteria for clinical trials and endorses the IMWG definition of partial response; the Minimal response section also distinguishes partial response or better from minimal response. The paper does not establish that overall response rate was the primary endpoint of the particular phase 2 study or that an independent review committee assessed it (pages not provided). (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [11] source
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Of the 19 deaths due to adverse events in our study, 12 were attributed to Covid-19, which was consistent with the higher mortality observed from Covid-19 in patients with hematologic cancers during this time frame.24”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
What the sources say
- Supportedcites [24] source
The citation supports the background comparison, not the citing authors’ own count of 12 COVID-19 deaths among 19 adverse-event deaths. The Discussion reports high COVID-19 mortality in patients with hematologic malignancies and says it was substantially higher than in the general population, while cautioning that the estimate may be elevated by the large proportion of hospitalized patients. (LLM, conf=0.92)
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“median, five previous therapy lines”
- Also stated in: § PATIENTS · plain
“Patients had received a median of 5 previous lines of therapy (range, 2 to 14)”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > Abstract > RESULTS
Strength:plain· not yet calibratedn = 165Tests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Also stated in: § PATIENTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Teclistamab exposure was sustained over the predetermined target level (6 μg per milliliter, based on the upper boundary of an experimentally determined range of the 90% maximal effective concentration) with a low peak-to-trough ratio (Fig. S3).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > PHARMACOKINETICS, IMMUNOGENICITY, AND BIOMARKERS
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Cytokine release syndrome occurred in 119 patients (72.1%). Most events occurred after step-up and cycle 1 doses, with 6 patients (3.6%) having cytokine release syndrome in cycle 2 or later. Most events of cytokine release syndrome were grade 1 or 2 in severity and fully resolved, except for one grade 3 event”
- Also stated in: § RESULTS · plain
“cytokine release syndrome (in 72.1% of the patients; grade 3, 0.6%; no grade 4)”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Strength:plain· not yet calibratedn = 119Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Response rates were lower in patients with extramedullary disease, stage III disease, and at least 60% marrow replacement by plasma cells and were higher in those who had received no more than three previous lines of therapy.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“thrombocytopenia (in 66 [40.0%])”
- Also stated in: § RESULTS · plain
“thrombocytopenia (in 40.0%; grade 3 or 4, 21.2%)”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Strength:plain· not yet calibratedn = 66Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A total of 68 patients (41.2%) died, with most deaths (41) attributed to progressive disease (Table S9). Nineteen patients died from adverse events, including 12 deaths from coronavirus disease 2019 (Covid-19). Five deaths were considered by investigators to be related to teclistamab”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In addition, reductions in soluble BCMA levels occurred during the first 4 cycles of treatment in 63 of 72 evaluable patients (88%) who had a partial response or better, whereas all the evaluable patients who did not have a response (9 of 9 patients) had increased levels of soluble BCMA.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > PHARMACOKINETICS, IMMUNOGENICITY, AND BIOMARKERS
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A total of 98 patients (59.4%) received at least 6 months of teclistamab treatment, and 79 patients (47.9%) received at least 9 months of treatment.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > PATIENTS
Strength:plain· not yet calibratedn = 98Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“All 165 patients reported having an adverse event (Table 2 and Table S5), which were grade 3 or 4 in 156 patients (94.5%).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Five patients had a total of 9 events of immune effector cell–associated neurotoxicity syndrome, all either grade 1 or 2. Of these 9 events, 7 were concurrent with cytokine release syndrome, and all 9 events resolved without discontinuation or dose reduction.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“neutropenia (in 117 patients [70.9%])”
- Also stated in: § RESULTS · plain
“neutropenia (in 70.9%; grade 3 or 4, 64.2%)”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Strength:plain· not yet calibratedn = 117Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Injection-site reactions were reported in 60 patients (36.4%); all such events were grade 1 or 2.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Strength:plain· not yet calibratedn = 60Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The median time until the onset of cytokine release syndrome was 2 days (range, 1 to 6) after the most recent dose, and the median duration was 2 days (range, 1 to 9).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Investigator-assessed neurotoxic events, including immune effector cell–associated neurotoxicity syndrome, were reported in 24 patients (14.5%).”
- Also stated in: § RESULTS · plain
“Neurotoxic events occurred in 24 patients (14.5%), including immune effector cell–associated neurotoxicity syndrome in 5 patients (3.0%; all grade 1 or 2).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Strength:plain· not yet calibratedn = 24Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“anemia (in 86 [52.1%])”
- Also stated in: § RESULTS · plain
“anemia (in 52.1%; grade 3 or 4, 37.0%)”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Strength:plain· not yet calibratedn = 86Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The median time until the first response was 1.2 months (range, 0.2 to 5.5), and the median time until a best response was 3.8 months (range, 1.1 to 16.8).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
Strength:plain· not yet calibratedn = 165Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“One patient had a dose reduction during cycle 21 because of recurrent neutropenia, and 104 patients (63.0%) skipped a dose because of adverse events. Two patients discontinued teclistamab because of adverse events (grade 3 adenoviral pneumonia and grade 4 progressive multifocal leukoencephalopathy).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As of March 16, 2022, 70 patients (42.4%) were continuing to receive treatment (Fig. S1), with a median treatment duration of 8.5 months (range, 0.2 to 24.4).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > PATIENTS
Strength:plain· not yet calibratedn = 70Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Infections occurred in 126 patients (76.4%); 74 patients (44.8%) had grade 3 or 4 infections.”
- Also stated in: § RESULTS · plain
“Infections were frequent (in 76.4%; grade 3 or 4, 44.8%).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Strength:plain· not yet calibratedn = 126Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Also stated in: § RESULTS · plain
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The overall depth of response was highlighted by the observation that 26.7% of the patients were found to have no minimal residual disease at a sensitivity level of 10−5; these patients made up 82% of those in whom minimal residual disease could be evaluated.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Cytopenias and infections were common; toxic effects that were consistent with T-cell redirection were mostly grade 1 or 2.”
- Also stated in: § DISCUSSION · plain
“Toxic effects were also common but were mainly of low grade and reversible.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > Abstract > CONCLUSIONS
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Also stated in: § DISCUSSION · plain
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The sponsor established a safety evaluation team to monitor patient safety throughout the phase 1 study. In phase 2, safety was monitored through continuous review by the sponsor.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > STUDY OVERSIGHT
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In addition, subgroup analyses suggest that patients who have received no more than three previous therapy lines may have a better response rate than those who have received more than three therapies, a finding that supports the use of teclistamab in earlier therapy lines (although the confidence intervals for this finding are wide).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Teclistamab redirects CD3+ T cells to BCMA+ myeloma cells, resulting in T-cell activation and subsequent lysis and death of BCMA+ cells.18”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites [18] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The study was conducted in accordance with the principles of the Declaration of Helsinki and the Good Clinical Practice guidelines of the International Council for Harmonisation.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > STUDY OVERSIGHT
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Toxic effects were also common but were mainly of low grade and reversible.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The median relative dose intensity was high, and dose reductions and discontinuations owing to adverse events were infrequent.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The safety and efficacy populations for this analysis included all the patients who had received at least one dose of teclistamab at the recommended phase 2 dose in phase 1 or phase 2 as of September 7, 2021.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > STATISTICAL ANALYSIS
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Response rates were also compared across various prespecified subgroups, including those defined according to cytogenetic risk, refractory status, and number of previous lines of therapy.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > STATISTICAL ANALYSIS
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“For phase 2, we determined that a sample size of 100 patients would provide a power of at least 85% to establish an overall response rate of more than 30% at a one-sided significance level of 0.025, assuming an overall response rate of at least 45%.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > STATISTICAL ANALYSIS
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
In the paper
“Adverse events in this phase 1–2 trial were common and included low-grade cytokine release syndrome and grade 3 or 4 cytopenia and infection in a patient population that has an increased susceptibility to infection due to the immunodeficiency associated with myeloma and immunosuppressive effects of previous myeloma therapies.23”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites [23] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Negativity for minimal residual disease was assessed by next-generation sequencing of DNA obtained from bone marrow aspirate (clonoSEQ assay, version 2.0 [Adaptive Biotechnologies]) with a threshold of 10−5 cells.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > END POINTS AND ASSESSMENTS
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The study protocol, amendments, and relevant documents were approved by the local independent ethics committee or institutional review board at each study site. All the patients provided written informed consent.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > STUDY OVERSIGHT
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“All the authors affirm that the trial was conducted in accordance with the study protocol and vouch for the accuracy and completeness of the data.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > STUDY OVERSIGHT
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
The paper relies on this without support.
Teclistamab is readily available.
“Teclistamab is readily available and has been associated with rapid onset of response after a median of approximately 1 month of treatment.”
The paper relies on this without support.
No CD3-redirecting therapy has been approved for the treatment of myeloma.
“Although clinical proof of concept has been obtained for other CD3-redirection platforms in other indications,19-21 no CD3-redirecting therapy has been approved for the treatment of myeloma.”
The paper relies on this without support.
Cross-trial comparisons are challenging to interpret owing to differences in study design and patient populations.
“Although cross-trial comparisons are challenging to interpret owing to differences in study design and patient populations, the response rates observed with teclistamab (63%) compare favorably with those of belantamab mafodotin”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Two BCMA-targeting bispecific antibodies, teclistamab and elranatamab, have been approved for use in patients with relapsed myeloma who have received at least 4 prior regimens.91,92”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [91]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“A number of BCMA-directed therapies, including belantamab mafodotin, idecabtagene vicleucel (ide-cel), ciltacabtagene autoleucel (cilta-cel) and teclistamab, have shown efficacy in clinical trials and are approved for the treatment of relapsed or refractory multiple myeloma4–9.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [4]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Similarly, patients with advanced disease stage (R-ISS stage III) have consistently shown poorer outcomes irrespective of the therapy received4–6,19–22.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In comparison to other BCMA-targeted T-cell-redirecting therapies, the rate of hematologic AEs with elranatamab was similar or lower after a similar follow-up4–6.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and favorable to the BCMA-targeting antibody–drug conjugate, belantamab mafodotin (ORR 32%, median DOR 11.0 months and median PFS 2.8 months) after a median follow-up of 12.4 months4,9,19,23.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [4]
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“Teclistamab and elranatamab are bispecific antibodies produce an immunotherapeutic effect by binding to BCMA on myeloma cells on one arm and CD3 on T cells with the other.91,92”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [91]
The cited source says what the claim attributes to it.
In the citing paper
“The primary endpoint in phase 2 was overall response rate per IMWG criteria,11 based on independent committee review, which was defined as the proportion of patients who had a partial response or better.”
From Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 study. (2025) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“Teclistamab, a bispecific antibody targeting CD3×BCMA,6 demonstrated deep and durable responses in heavily pretreated RRMM in the phase 1/2 MajesTEC-1 study.7,8”
From Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma (2026) · cites this paper as [8]
The cited source says what the claim attributes to it.
In the citing paper
“Cytokine release syndrome incidence was lower than that observed with teclistamab monotherapy in MajesTEC-1 (60.1% vs. 72.1%, respectively),8 with most events being grade 1 and occurring during the step-up dosing schedule.”
From Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma (2026) · cites this paper as [8]
The cited source says what the claim attributes to it.
In the citing paper
“In this trial, 165 RRMM patients were treated with Teclistamab, and the following key outcomes were observed 63.0% ORR, 58.8% VGPR, and 39.4% CR. These results demonstrate the significant clinical activity of Teclistamab in RRMM patients who have received multiple prior lines of therapy. The high ORR, VGPR rate, and CR rate indicate substantial anti-myeloma activity of Teclistamab. Additionally, t”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [209]
The cited source says what the claim attributes to it.
In the citing paper
“The lower response rate observed in patients with extramedullary disease reflects the historically poor prognosis in this subgroup and has also been observed with other anti-BCMA-targeted agents such as belantamab mafodotin and teclistamab4,19.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [4]
Citations
Cites
Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675
Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061
Self-citationIdecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
Munshi, N. C., Anderson, L. D., Shah, N., Madduri, D., Berdeja, J., Lonial, S., Raje, N., Lin, Y., Siegel, D., Oriol, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2024850 · Cited by 2,560
Self-citationBerdeja, J. G., Madduri, D., Usmani, S. Z., Jakubowiak, A., Agha, M., Cohen, A. D., Stewart, A. K., Hari, P., Htut, M., Lesokhin, A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00933-8 · Cited by 1,756
Self-citationRajkumar, S. V., Harousseau, J.-L., Durie, B., Anderson, K. C., Dimopoulos, M., Kyle, R., Blade, J., Richardson, P., Orlowski, R., Siegel, D., et al. (2011) · Blood · doi:10.1182/blood-2010-10-299487 · Cited by 1,036
Self-citationMultiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
Dimopoulos, M. A., Moreau, P., Terpos, E., Mateos, M. V., Zweegman, S., Cook, G., Delforge, M., Hájek, R., Schjesvold, F., Cavo, M., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.014 · Cited by 900
Self-citationLonial, S., Lee, H. C., Badros, A., Trudel, S., Nooka, A. K., Chari, A., Abdallah, A.-O., Callander, N., Lendvai, N., Sborov, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30788-0 · Cited by 812
Self-citationVijenthira, A., Gong, I. Y., Fox, T. A., Booth, S., Cook, G., Fattizzo, B., Martín-Moro, F., Razanamahery, J., Riches, J. C., Zwicker, J., et al. (2020) · Blood · doi:10.1182/blood.2020008824 · Cited by 625
Shah, N., Chari, A., Scott, E., Mezzi, K., & Usmani, S. Z. (2020) · Leukemia · doi:10.1038/s41375-020-0734-z · Cited by 490
Self-citationBispecific T‐cell engagers for cancer immunotherapy
Huehls, A. M., Coupet, T. A., & Sentman, C. L. (2014) · Immunology and Cell Biology · doi:10.1038/icb.2014.93 · Cited by 478
Flagged first, then by citations
Cited by
Sorted by citations
Items 501–600 of 1,251
Qureshi, Z. A., Jamil, A. R., Altaf, F., Siddique, R., & Ahmed, F. (2024) · Annals of Hematology · doi:10.1007/s00277-024-06078-z · Cited by 6
Current State of Evidence on Definitions and Management of High-Risk Multiple Myeloma
Lal, B. M., van Rhee, F., & Hadidi, S. A. (2025) · Current Oncology Reports · doi:10.1007/s11912-025-01639-5 · Cited by 7
“The ORR benefits were maintained in patients with high-risk disease [120].”
Goel, U., Zanwar, S., Cowan, A. J., Banerjee, R., Khouri, J., & Dima, D. (2025) · Cancer Management and Research · doi:10.2147/cmar.s510408 · Cited by 5
“63,82,83 However, patients who are selected and ultimately infused with CAR T tend to have a slower disease tempo and otherwise favorable performance status, which limits direct comparisons of these trials.”
Restarting teclistamab and talquetamab after prolonged dose delay may not require re–step-up dosing
Tan, C. R. C., Wang, A. X., Nemirovsky, D., Derkach, A., Shekarkhand, T., Hamadeh, I. S., Maclachlan, K. H., Hultcrantz, M. L., Hassoun, H., Mailankody, S., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024015344 · Cited by 6
Self-citationTalquetamab in heavily pretreated patients with multiple myeloma, including BCMA-refractory
Vegel, A. J., Loeffler, B. T., Lochner, J. S., Friend, R. N., Habib, A., McKenna, M., Snyder, J. A., Green, K., Dileo, R., Patrus, G., et al. (2025) · Blood Immunology & Cellular Therapy · doi:10.1016/j.bict.2025.100001 · Cited by 6
Bal, S., Schmidt, T. M., Costa, L. J., & Callander, N. S. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2123231 · Cited by 6
Cerchione, C., Grant, S. J., & Ailawadhi, S. (2023) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_390202 · Cited by 7
Infection rates are high across the multiple myeloma continuum, not just with bispecific antibodies.
Rubinstein, S., & Derman, B. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.05.014 · Cited by 6
THE ROLE OF CAR T-CELL THERAPY IN THE ERA OF BISPECIFIC ANTIBODIES
Nath, K. D., Mailankody, S., & Usmani, S. Z. (2023) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2023.05.011 · Cited by 8
Self-citationUpdate on bi-specific monoclonal antibodies for blood cancers
Shouse, G. (2023) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000966 · Cited by 4
Kulkarni, A., Bazou, D., & Santos-Martínez, M. J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242115855 · Cited by 6
“Similarly, both Janssen’s Teclistamab and Pfizer’s Elrexfio (elranatamab-bcmm) bispecific antibodies target the B-cell maturation antigen (BCMA)-cluster of differentiation three (CD3) (NCT04557098, NCT04649359) in relapsed/refractory MM patients [18,19].”
Valković, T., Marcelic, L., & Valković, F. (2024) · Therapeutic Advances in Infectious Disease · doi:10.1177/20499361241238518 · Cited by 6
“26”
Targeting GPRC5D in multiple myeloma
Elemian, S., & al Hadidi, S. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2343114 · Cited by 7
“Notably, both agents resulted in deep and relatively long-lasting responses in patients, with a unique safety profile [23–25].”
BackgroundWillemin, M., Lin, S. X. W., Zwart, L. D., Wu, L. S., Miao, X., Verona, R. I., Banerjee, A., Liu, B., Kobos, R., Qi, M., et al. (2024) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.13144 · Cited by 6
“…the efficacy and safety of teclistamab at the recommended phase II dose (RP2D; once weekly 1.5 mg/kg subcutaneous) in patients with TCE RRMM. 19 To minimize the risk of CRS, teclistamab is administered using two step-up doses (0.06 and 0.3 mg/kg) prior to the first treatment dose (1.5…”
BackgroundMethodInfluentialSelf-citationAllogeneic stem cell transplantation in multiple myeloma: is there still a place?
Liberatore, C., Fioritoni, F., & Ianni, M. D. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1402106 · Cited by 7
Aiming for the cure in myeloma: Putting our best foot forward
Bar, N., Firestone, R., & Usmani, S. Z. (2023) · Blood Reviews · doi:10.1016/j.blre.2023.101116 · Cited by 6
Self-citationSOHO State of the Art Updates and Next Questions: Will CAR-T Replace ASCT in NDMM
Jurgens, E. M., & Usmani, S. Z. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2024.01.001 · Cited by 6
Self-citationSingh, R., Jones, R. J., Shirazi, F., Li, Q., Zou, J., Hong, S., Wang, H., Lee, H. C., Patel, K. K., Wan, J., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-3843028/v1 · Cited by 6
“…example, lower response rates were noted among high-risk patients in the pivotal trials of the ADC belantamab mafodotin (8), the bispeci�c teclistamab (9), and the CAR T-cell product idecabtagene vicleucel (10), which were the �rst drugs in each mechanistic category to achieve regulatory approvals.”
BackgroundSpatial imaging unlocks the potential of charting multiple myeloma and extramedullary disease
Desantis, V., Andriano, A., Düking, T., Hartwig, O., Ingravallo, G., Biondo, M., Botta, C., Ria, R., Vacca, A., & Solimando, A. G. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01699-x · Cited by 12
Martino, E. A., Caridà, G., Lofaro, D., Bruzzese, A., Labanca, C., Mendicino, F., Lucia, E., Olivito, V., Puccio, N., Neri, A., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.105514 · Cited by 7
Chen, W., Cai, Z., Chim, C. S., Chng, W. J., Du, J., Fu, C., Gao, W., Hanamura, I., Hou, J. M., Huang, J., et al. (2025) · Clinical Hematology International · doi:10.46989/001c.141401 · Cited by 5
Poels, K. E., Elmeliegy, M. A., Hibma, J. E., Wang, D., Musante, C. J., & Shtylla, B. (2025) · npj Systems Biology and Applications · doi:10.1038/s41540-025-00585-z · Cited by 10
“HighersBCMAlevelshavebeenassociatedwithpooreroutcomes 43,50,51 , which may be due to its correlation with clinically relevant covariates (e.g., tumor burden and staging) or through its impact as a drug sink.”
First case report of talquetamab use in AL amyloidosis
Even‐Zohar, N. G., Aumann, S., Shaulov, A., Haran, A., Nachmias, B., Lebel, E., Lehmann‐Werman, R., & Gatt, M. E. (2025) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2025.2556175 · Cited by 5
“Talquetamab is the first GPRC5d targeting bispecific T-cell engager approved for treatment of relapsed or refractory MM, based on remarkable efficacy, and limited toxicity [19,28–30].”
Beyond monospecificity: The modular revolution of bispecific immunotherapeutics
Fattahi, A. S., & Haghighi, E. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.105003 · Cited by 7
Snyder, J. A., Atrash, S., Paul, B. A., et al. (2025) · Cancers · doi:10.3390/cancers17213569 · Cited by 5
Milandri, J., Jaillard, M., Laffineur, M., et al. (2025) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2025.111038 · Cited by 5
Einsele, H., Moreau, P., Bahlis, N. J., Bhutani, M., Vincent, L., Karlin, L., Perrot, A., Goldschmidt, H., van de Donk, N. W. C. J., Ocio, E. M., et al. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03409-y · Cited by 5
Self-citationIrfan, S., Ayoobkhan, F. S., Vojjala, N., Qureshi, R., Rahman, R. L., Kamboj, I., Abdallah, A.-O. A., McGuirk, J. P., Mahmoudjafari, Z., Lutfi, F. U., et al. (2025) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2025.12.947 · Cited by 6
Korst, C. L. B. M., Plattel, W. J., de Kort, E., Smits, F., Croockewit, A. J., Levin, M., Westerman, M., de Weerdt, O., Nijhof, I. S., Wegman, J. J., et al. (2026) · The Lancet Haematology · doi:10.1016/s2352-3026(25)00298-4 · Cited by 5
Self-citationLandscape of T-cell engagers in solid tumors
Garcia-Lorenzo, E., Dorta, M., Doger, B., Pedregal, M., & Moreno, V. (2026) · The Oncologist · doi:10.1093/oncolo/oyag129 · Cited by 5
“13 Monitoring strategies for T-cell engagers vary widely across institutions.”
InfluentialChen, L., Aleman, A., Larráyoz, M., Chiu, H., Zhao, J., Oekelen, O. V., Kelly, G., Kim‐Schulze, S., Laganà, A., Jagannath, S., et al. (2026) · Blood · doi:10.1182/blood.2025030891 · Cited by 7
Bal, S., Htut, M., Nadeem, O., Anderson, L. D., Gregory, T. K., Kocoglu, M. H., Rossi, A., Martin, T. G., Egan, D. N., Costa, L. J., et al. (2026) · Blood · doi:10.1182/blood.2025030750 · Cited by 7
Self-citationTeclistamab for treatment-refractory autoimmune diseases: a multicentre case series
Albach, F. N., Phithak, E., Biesen, R., et al. (2026) · Annals of the Rheumatic Diseases · doi:10.1016/j.ard.2026.05.021 · Cited by 5
“Teclistamab, a B-cell maturation antigen (BCMA)-directed bispeci fi c antibody approved for relapsed multiple myeloma (MM) [3], targets plasmablasts, long-lived plasma cells, and their BCMA-expressing memory B-cell pre-cursors, making BCMA an attractive target in refractory AID.”
Bispecific antibodies for multiple myeloma: past, present and future
Ochi, T., Konishi, T., & Takenaka, K. (2024) · International Journal of Hematology · doi:10.1007/s12185-024-03766-4 · Cited by 6
“%) also occurred, suggesting the need for management of these adverse events [21].”
InfluentialSupportive care measures for bispecific T-cell engager therapies in haematological malignancies
Chen, L., & Kothari, J. (2024) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0000000000000699 · Cited by 5
“Cytopenias and infections are common AEs of BMCA-CD3 TCEs; for example, nearly 65% of patients treated with teclistamab experienced grade ≥ 3 neutropenia and 13% developed grade ≥ 3 pneumonia [15].”
BackgroundInfluentialDerman, B. A., Roach, M., Lin, D., Wu, B., Murphy, R., Kim, N., Doyle, M., Prood, N., Fowler, J., Marshall, A., et al. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2352856 · Cited by 6
Multiple myeloma and infections in the era of novel treatment modalities
Akhmedov, M., Zeynalova, P. A., & Феденко, А. А. (2024) · Leukemia Research · doi:10.1016/j.leukres.2024.107544 · Cited by 6
Cicala, G., Russo, G., Santoro, V., Franchina, T., Silvestris, N., Santarpía, M., Spina, E., & Barbieri, M. A. (2024) · Pharmaceuticals · doi:10.3390/ph17101266 · Cited by 5
“Elotuzumab improves median progression-free survival (PFS) to 19.4 months [6], while teclistamab shows a median PFS of 11.3 months [7].”
BackgroundInfluentialMeasurable Residual Disease Testing in Multiple Myeloma Following T-Cell Redirecting Therapies
Shim, K. G., & Fonseca, R. (2024) · Cancers · doi:10.3390/cancers16193288 · Cited by 6
“%) were reported [66,91].”
BackgroundTrispecific anti-CD3/BCMA/CD38 antibodies for multiple myeloma: a patent evaluation of US20240132615
Bandala, C., Flores-Robles, D., Sierra-Martínez, P., et al. (2024) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2024.2423018 · Cited by 5
Are we there yet? CAR ‐T therapy in multiple myeloma
Mirvis, E., & Benjamin, R. (2024) · British Journal of Haematology · doi:10.1111/bjh.19896 · Cited by 8
Wang, H., Liang, L., Xie, Y., Gong, H., Fan, F., Wen, C., Yu, J., Lei, S., Qiu, X., Peng, H., et al. (2024) · Oncogene · doi:10.1038/s41388-024-03245-4 · Cited by 6
“Cell culture, chemicals and antibodies, cell viability assay, et, additional methods are described in the Supplementary Material.”
Hungria, V., Gaiolla, R. D., Gálvez, K., Remaggi, G., Schutz, N. P., Bittencourt, R., Maiolino, Â., Quintero, G., Cugliari, M. S., Braga, W. M. T., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024013838 · Cited by 5
Ram, M., Fraser, M., Santos, J. V. D., Tasakis, R. N., Islam, A., Abo-Donia, J. U., Parekh, S. S., & Laganà, A. (2024) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s350238 · Cited by 8
Extramedullary myeloma in the era of CAR T-cell and bispecific antibody therapies.
Sanchez, L. J., & Richard, S. (2025) · Seminars in hematology (Print) · doi:10.1053/j.seminhematol.2025.02.001 · Cited by 6
Approaches To Managing Relapsed Myeloma: Switching Drug Class or Retreatment With Same Drug Class?
Vijjhalwar, R., Kannan, A., Fuentes-Lacouture, M. C., & Ramasamy, K. (2025) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-025-02008-9 · Cited by 6
Pomalidomide combinations are a safe and effective option after daratumumab failure
Brioli, A., Gengenbach, L., Mancuso, K., Binder, M., Ernst, T., Heidel, F. H., Stauch, T., Zamagni, E., Hilgendorf, I., Hochhaus, A., et al. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-04637-x · Cited by 5
Determinants of response and resistance to T cell-engaging therapies in multiple myeloma
Midha, S., & Anderson, K. C. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00775-w · Cited by 5
Baert, L., Manfroi, B., Quintero, M., Chavarria, O., Barbon, P.-V., Clement, E., Zeller, A., Kuppevelt, T. H. V., Stürm, N., Moreaux, J., et al. (2023) · Matrix Biology · doi:10.1016/j.matbio.2023.05.005 · Cited by 6
Recomendações do Grupo Português do Mieloma Múltiplo para Tratamento do Mieloma Múltiplo
Joao, C. M., Bergantim, R., Santos, J., Afonso, C., Bernardo, P. A. V. D. C., Coelho, H. G. B., Costa, C. M. A., Esteves, G. V., de Freitas, J. G., Gerivaz, R., et al. (2023) · Acta Médica Portuguesa · doi:10.20344/amp.19037 · Cited by 6
Piron, B., Bastien, M., Antier, C., et al. (2023) · Haematologica · doi:10.3324/haematol.2023.282919 · Cited by 5
Self-citationExploring the impact of dexamethasone on gene regulation in myeloma cells
Gaborit, V., Cruard, J., Guérin‐Charbonnel, C., Derrien, J., Alberge, J.-B., Douillard, E., Devic, M., Deshayes, S., Campion, L., Westermann, F., et al. (2023) · Life Science Alliance · doi:10.26508/lsa.202302195 · Cited by 8
“Recently, T-cell-engaging therapies administrating bispecific antibodies targeting CD3 and B-cell maturation antigen for patients who had relapsed or refractory MM, in which Dex is delivered in premedication, showed a promising efficacy in depth and duration of the response (Moreau et al, 2022).”
BackgroundSelf-citationMultiple myeloma treatment: one bridge closer
Lucca, L. E. (2023) · Blood · doi:10.1182/blood.2023022470 · Cited by 5
Bispecific Antibodies in the Treatment of Multiple Myeloma
Zhou, X., Xiao, X., Kortuem, K. M., & Einsele, H. (2024) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2023.12.003 · Cited by 5
Genome-wide CRISPR/Cas9 screen identifies regulators of BCMA expression on multiple myeloma cells
Ajore, R., Mattsson, J., Pertesi, M., Ekdahl, L., Ali, Z., Hansson, M., & Nilsson, B. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-00986-z · Cited by 5
“Currently, new immunotherapies are being introduced that utilize BCMA to redirect the patient ’ s T-cells to kill MM cells, using either chimeric antigen receptor (CAR) T-cells [1] or bispeci fi c BCMAxCD3 T-cell-engaging antibodies [2, 3].”
Carvalho, N. B., de Freitas, V. L. T., Seguro, F. S., Bezerra, R. C., Fatobene, G., Nakanishi, É. Y. S., Visnadi, H., Martınez, G., Batista, M. V., Rocha, V., et al. (2024) · Revista do Instituto de Medicina Tropical de São Paulo · doi:10.1590/s1678-9946202466010 · Cited by 5
“…9 , proteasome inhibitors (PI, bortezomib) 10 , 11 , and anti-CD38 monoclonal antibodies (anti-CD38, anti-BCMA [B-cell maturation antigen] or anti-SLAMF-7 [Signaling lymphocytic activation molecule F7] 11 - 13 , bispecific T-cell engagers 14 , and chimeric antigen receptor T-cell therapy) 15 .”
Garderet, L., Gras, L. A., Köster, L., et al. (2024) · Haematologica · doi:10.3324/haematol.2023.284520 · Cited by 5
“26 Other immunotherapies such as T-cell engagers 27 and chimeric antigen receptor T cells, 28 alone or in combinations, have rapidly entered the clinical arena and in preliminary experiences, they seem to be administered safely to patients with renal insufficiency.”
BackgroundCurrent status of bispecific antibodies and CAR-T therapies in multiple myeloma
Szlasa, W., & Dybko, J. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112043 · Cited by 6
Tryggestad, S. S., Roseth, I. A., Aass, K. R., Ørning, N. E. H., Mjelle, R., Hella, H., & Standal, T. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1393906 · Cited by 6
Treatment of AL amyloidosis in the era of novel immune and cellular therapies
Sarubbi, C., Abowali, H., Varga, C., & Landau, H. J. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1425521 · Cited by 8
“…targeting CD3 expressed on the surface of T cells and BCMA expressed on MM cells represent another effective T cell redirecting strategy that has demonstrated promising results in MM, leading to the FDA approval of two commercially available products, teclistimab and elranatamab (36, 37).”
BackgroundSafety outcomes of teclistamab accelerated dose escalation
Kawasaki, Y., Steele, A. P., Rosenberg, A. S., et al. (2024) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552241268429 · Cited by 5
Precision medicine for multiple myeloma: The case for translocation (11;14)
Bazarbachi, A. H., Avet‐Loiseau, H., Harousseau, J., Bazarbachi, A., & Mohty, M. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102823 · Cited by 5
Antibody-Based Therapies for Peripheral T-Cell Lymphoma
Shafagati, N., Paul, S., Rozati, S., & Sterling, C. H. (2024) · Cancers · doi:10.3390/cancers16203489 · Cited by 7
A second look at secondary hypogammaglobulinemia
Monahan, R., Otani, I. M., Lehman, H. K., & Mustafa, S. S. (2024) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2024.12.003 · Cited by 6
Advancements in bispecific antibodies for multiple myeloma: What's new and what lies ahead
Mouhieddine, T. H., Costa, B. A., & Richter, J. R. (2024) · Seminars in Hematology · doi:10.1053/j.seminhematol.2024.12.001 · Cited by 6
Improving CD3 bispecific antibody therapy in solid tumors using combination strategies
Lloyd, K. A., Middelburg, J., Ovcinnikovs, V., Pencheva, N., Kemper, K., & van Hall, T. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1548446 · Cited by 5
Emerging GPRC5D-Targeted therapies for multiple myeloma: a comprehensive review
Pan, D., Kumar, A. D., Lipof, J. J., Chung, A., Wolf, J. L., Martin, T. G., Arora, S., Sayre, P. H., & Chari, A. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2511179 · Cited by 5
“Of patients treated with the 0.8 mg/kg dose level of talquetamab in MonumenTAL-1, 34% had infections (7% grade ≥ 3), compared to 76% in teclistamab-treated patients in MajesTEC-1 (45% grade ≥ 3) [12,38].”
InfluentialSelf-citationIberdomide with dexamethasone: a new backbone for myeloma treatment?
Rodríguez‐Otero, P., & Miguel, J. F. S. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00322-2 · Cited by 6
Self-citationWei, J., Zheng, H., Dai, S., & Liu, M. (2024) · Heliyon · doi:10.1016/j.heliyon.2023.e23929 · Cited by 5
Olivieri, D. J., & Banerjee, R. K. (2024) · JCO Oncology Practice · doi:10.1200/op-24-00921 · Cited by 8
Kegyes, D., Moisoiu, V., Constantinescu, C. S., Tănase, A., Ghiaur, G., Einsele, H., Tomuleasa, C., Lazarus, H. M., & Gale, R. P. (2024) · Blood Reviews · doi:10.1016/j.blre.2024.101254 · Cited by 5
Ursino, M., Villacampa, G. J., Rekowski, J., Dimairo, M., Solovyeva, O., Ashby, D., Berlin, J. D., Boix, O., Calvert, M., Chan, A., et al. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102988 · Cited by 6
“” 44 This example lacks a more explicit explanation regarding the rationale behind selecting a target risk/toxicity rate .”
Treatment patterns and clinical outcomes for multiple myeloma in Korean patients: a database study
Yoon, J., Jung, J., Park, B., Lee, E., Park, Y. S., Yoon, S., & Eom, H. (2025) · BMC Cancer · doi:10.1186/s12885-025-13615-0 · Cited by 4
“Bispecific antibodies, such as talquetamab and teclistamab, also represent newly available options with various molecular targets and relatively tolerable safety issues [19–21].”
Bekadja, M. A., Gras, L. A., Baaij, L. G. A., et al. (2025) · Cytotherapy · doi:10.1016/j.jcyt.2025.02.008 · Cited by 4
Sanchez, J., Pierrillas, P. B., Frey, N., Lotz, G. P., Jönsson, S., Friberg, L. E., & Frances, N. (2025) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.70019 · Cited by 4
Yadav, R., Chaudary, J. K., Bisht, K., Dhamija, P., Chaudhary, P. K., Nath, U. K., & Jain, N. K. (2025) · Seminars in Oncology · doi:10.1016/j.seminoncol.2025.152390 · Cited by 6
Molecular and immunological determinants of long-term survival in multiple myeloma
Kasomva, K., Yadav, K., Janz, S., Dhakal, B., & Rao, S. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025016829 · Cited by 4
“20,23,61 This redirection of cytotoxic T cells enables potent, antigen-specific killing independent of native TCR specificity.”
Park, A. K., Monroy, I., Ren, Y., Lu, C., Chaurasiya, S., Valencia, H., Lent-Koop, J., Cook, C., Kang, S., Lopez, L. S., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-011051 · Cited by 5
Therapeutic options for extramedullary involvement in multiple myeloma
Zhao, J., Cui, Y., & Fang, B. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01821-w · Cited by 8
“Compared with other emerging therapies, single-agent belantamab demonstrated activity comparable to BsAbs but lower than CAR-T cell therapy in patients with EMD [88, 91].”
Cazaubiel, T., Decaux, O., Royer, B., Caillot, D., Bobin, A., Belhadj‐Merzoug, K., Macro, M., Vincent, L., Perrot, A., Mohty, M., et al. (2025) · Clinical Hematology International · doi:10.46989/001c.143641 · Cited by 4
Self-citationMian, H. S., Harper, J. S., Le, H. H., Fu, A. Z., Patel, S., Zhang, X., & Fonseca, R. (2025) · eJHaem · doi:10.1002/jha2.70145 · Cited by 4
“…BCMA-targeting therapies have been approved for patients with TCE MM in the later-line setting, including the bispecific antibodies teclistamab [11, 12] and elranatamab [13] and the CAR-T therapies idecabtagene vicleucel (ide-cel) [14, 15] and ciltacabtagene autoleucel (cilta-cel) [16, 17], all of…”
Current experiences with teclistamab in patients with multiple myeloma and renal impairment
Dimopoulos, M. A., Cohen, Y. C., Perrot, A., Pianko, M. J., Faber, E. A., Leung, N., Mateos, M., & Nooka, A. K. (2025) · Expert Review of Hematology · doi:10.1080/17474086.2025.2567296 · Cited by 4
“Teclistamab was dosed according to the MajesTEC-1 protocol without adjustments for RI status, which was not a consideration in this study [18].”
InfluentialSelf-citationPredictors of Delayed Responses to Teclistamab in Multiple Myeloma After Initial Non‐Response
Banerjee, R. K., Kaur, G., Razzo, B. M., et al. (2025) · American Journal of Hematology · doi:10.1002/ajh.70108 · Cited by 4
Self-citationJurgens, E. M., Shekarkhand, T., Rueda, C., Nemirovsky, D., Derkach, A., Firestone, R., Miller, K. W. P., Costa, B. A., Rajeeve, S., Lesokhin, A. M., et al. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01393-8 · Cited by 4
“Dear Editor, Bispeci fi c antibodies (BsAbs) have demonstrated deep and durable responses in patients with relapsed/refractory multiple myeloma (RRMM) [1 – 3].”
Self-citationParola, S., & Colombo, I. (2025) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2025.1002345 · Cited by 5
Tang, T. F., Cheong, C. S., Looi, C. Y., Wong, W. F., & Gan, G. G. (2025) · Medicina · doi:10.3390/medicina61122113 · Cited by 7
“…approved BCMA × CD3 full-length IgG4 bispecific antibody with an Fc-silenced backbone enabling FcRn-mediated recycling, providing a half-life of approximately 2 to 3 weeks and allowing subcutaneous step-up administration followed by weekly maintenance in the MajesTEC-1 trial (NCT03145181) [31,32].”
Talquetamab in Japanese patients with relapsed/refractory multiple myeloma in the MonumenTAL-1 study
Ito, S., Kuroda, Y., Sunami, K., Matsue, K., Imada, K., Tamura, H., Fujikawa, E., Yamazaki, H., Takamoto, M., Pei, L., et al. (2025) · International Journal of Hematology · doi:10.1007/s12185-025-04134-6 · Cited by 4
“…events generally occurred early during step-up and Cycle 1 Day 1 doses, were all low grade (1/2), and did not result in treatment discontinuations; these data closely align with the global MonumenTAL-1 cohorts and are consistent with other T-cell redirecting bispecific antibodies in RRMM [33, 34].”
Self-citationZhou, K., Ebben, L., Dhakal, B., & Vallatharasu, Y. (2026) · JCO Oncology Practice · doi:10.1200/op-25-00748 · Cited by 4
Segers, F., & Delforge, M. (2026) · Targeted Oncology · doi:10.1007/s11523-025-01189-7 · Cited by 4
“Seventy-percent of patients with neutropenia received growth factors in the MajesTEC-1 trial and one patient had a dose reduction because of neutropenia [39].”
InfluentialSelf-citationÇetiner, T., Bilek, M. Ç., Kirezli, S. A., Üçüncü, G. Y., Ataş, Ü., İltar, U., Yücel, O. K., Çakın, Ö., Karaali̇, K., & Salim, O. (2026) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552261417343 · Cited by 5
Cell Therapies and Bispecific Engagers: Redefining Strategies against Checkpoint Resistance
Laubli, H. P., König, D., Donia, M., Binder, M., & Zippelius, A. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-3694 · Cited by 5
Tiny warriors, big impact: targeted immunotherapy in kidney diseases
Kurzhagen, J. T., Laqua, W., Schett, G. A., Grieshaber‐Bouyer, R., Rabb, H., Noel, S., & Schiffer, M. (2026) · Kidney International · doi:10.1016/j.kint.2026.01.032 · Cited by 5
FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial
Cohen, A. D., Richter, J. R., Trudel, S., Lesokhin, A. M., Laubach, J. P., Thomas, S. K., Harrison, S. J., Costa, L. J., Spencer, A. G., Fonseca, R., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04522-3 · Cited by 7
“Immunogenicity samples were obtained at baseline; before dosing in cycles 2, 3 and 4; and subsequently at every even-numbered cycle (cycles 6–16).”
InfluentialSelf-citationBCMA Directed Bispecific Antibody Induced Tumor Flare in Multiple Myeloma
Nagarajan, C., Jo, M. W. E., & Martin, T. G. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2024.03.002 · Cited by 4
Self-citationLee, H. C., Ramasamy, K., Macro, M., et al. (2024) · European Journal Of Haematology · doi:10.1111/ejh.14214 · Cited by 4
Lal, B. M., Alzubi, M., Alrawabdeh, J. A., Shaughnessy, J. D., Zhan, F., Siegel, E. R., Schinke, C., Thanendrarajan, S., Zangari, M., van Rhee, F., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024015648 · Cited by 5
“8,9,16,17 In conclusion, prior exposure to belantamab adversely affects the ef fi cacy of ide-cel therapy in RRMM, with worse outcomes observed in patients who responded to belantamab.”
Regulatory Approval of CAR‐T Cell and BsAb Products for Lymphoid Neoplasms in the US, EU, and Japan
Matsuda, K., Nonami, A., Shinohara, K., & Nagai, S. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3645 · Cited by 4
“20 In the United States, all indications in the CAR-T group were granted regular approval, whereas those in the BsAb groups were granted accelerated approvals, and conducting subsequent confirmatory trials was required to obtain regular approvals.”
Teclistamab‐Induced Remission of Chronic Immune Thrombocytopenia in a Patient With Multiple Myeloma
Quevedo‐Salazar, R., Yáñez‐Reyes, J. M., González‐López, E. E., et al. (2025) · eJHaem · doi:10.1002/jha2.70062 · Cited by 4
“Teclistamab, a bispecific antibody targeting B-cell maturation antigen (BCMA) on plasma cells and CD3 on T cells, has demonstrated efficacy in relapsed/refractory multiple myeloma (MM) [7].”
SOHO State of the Art Updates and Next Questions | Late/Deferred ASCT in Myeloma
Mo, C. C., Liu, Y., Hartley-Brown, M. A., Nadeem, O., Midha, S., & Richardson, P. G. G. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.06.003 · Cited by 4
Tsang, C., O’Reilly, J. E., Carpenter, L., Duffield, C., Tunaru, F., Wallis, J., Perkins, A., Price, T., Wood, S., & Ramasamy, K. (2025) · BMC Cancer · doi:10.1186/s12885-025-14624-9 · Cited by 4
“Several novel bispecific therapies [6–8] have demonstrated promising efficacy in treating RRMM in clinical trials.”
Metadata
- Authors
- Moreau, P., Garfall, A. L., van de Donk, N. W. C. J., Nahi, H., San-Miguel, J. F., Oriol, A., Nooka, A. K., Martin, T., Rosinol, L., Chari, A., Karlin, L., Benboubker, L., Mateos, M.-V., Bahlis, N., Popat, R., Besemer, B., Martínez-López, J., Sidana, S., Delforge, M., Pei, L., Trancucci, D., Verona, R., Girgis, S., Lin, S. X. W., Olyslager, Y., Jaffe, M., Uhlar, C., Stephenson, T., Van Rampelbergh, R., Banerjee, A., Goldberg, J. D., Kobos, R., Krishnan, A., & Usmani, S. Z.
- Affiliations
- Karolinska University Hospital (SE)
- From the Hematology Clinic, University Hospital Hôtel-Dieu, Nantes (P.M.), Service d’Hématologie Clinique, Centre Hospitalier Lyon Sud, Pierre-Bénite (L.K.), and Service d’Hématologie et Thérapie Cellulaire, Hôpital Bretonneau, Centre Hospitalier Régional Universitaire, Tours (L.B.) — all in France; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia (A.L.G.), and Janssen Research and Development, Spring House (R.V., S.G., S.X.W.L., C.U., T.S., A.B.) — both in Pennsylvania; the Department of Hematology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam (N.W.C.J.D.); Karolinska University Hospital at Huddinge, Stockholm (H.N.); Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Investigación Sanitaria de Navarra, Pamplona (J.F.S.-M.), Institut Català d’Oncologia and Institut Josep Carreras, Hospital Germans Trias i Puj...
- City Of Hope National Medical Center (US)
- Memorial Sloan Kettering Cancer Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-08-11
- Volume
- 387
- Issue
- 6
- Pages
- 495-505
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC10587778
- OpenAlex
- W4282033105
- Cited by
- 1,269
- References
- 25
- Citations by year
- 2026: 335 · 2025: 341 · 2024: 320 · 2023: 231 · 2022: 39
- FWCI
- 169.47
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Lirias (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Janssen Research & Development, LLC
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- teclistamab, relapsed/refractory multiple myeloma, bispecific T-cell engagers, overall response rate, minimal residual disease negativity, progression-free survival, cytokine release syndrome, neurotoxicity, dose-limiting toxicity, subcutaneous administration, immunotherapy safety and efficacy
- MeSH terms
- Antineoplastic Agents, Immunological, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Humans, Injections, Subcutaneous, Multiple Myeloma, Neoplasm Recurrence, Local, Recurrence, T-Lymphocytes, CD3 Complex, Antibodies, Bispecific, B-Cell Maturation Antigen, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
